Stoke Therapeutics (STOK) EBITDA Margin (2022 - 2026)
Stoke Therapeutics' quarterly EBITDA Margin came in at 813.31% in Q1 2026, down 88452.0% year-on-year from N/an in Q1 2025, and up 80.28% quarter-over-quarter from 4125.32% in Q4 2025.
Stoke Therapeutics has reported EBITDA Margin for 5 years, with the latest figure at 813.31% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 88452.0% year-over-year to 813.31%; the trailing twelve-month figure through Mar 2026 stood at 529.23% (down 55551.0% YoY), and the FY2025 full-year result was 3.36%, up 24041.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 813.31%, up from 4125.32% in the prior quarter.
- The five-year high for EBITDA Margin was 71.22% in Q1 2025, with the low at 4125.32% in Q4 2025.
- Average EBITDA Margin over 5 years is 810.76%, with a median of 734.89% recorded in 2023.
- Year-over-year, EBITDA Margin surged 90996 bps in 2024 and slumped 407757 bps in 2025.
- Tracing STOK's EBITDA Margin over 5 years: stood at 768.88% in 2022, then slipped by 25 bps to 957.71% in 2023, then soared by 95 bps to 47.75% in 2024, then sank by 8539 bps to 4125.32% in 2025, then jumped by 80 bps to 813.31% in 2026.
- The last three EBITDA Margin figures came in at 813.31% (Q1 2026), 4125.32% (Q4 2025), and 357.38% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.24% |
| 10 | Stoke Therapeutics | 1.92 Bn | 1.92 Bn | - | -813.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -813.31% |
| Dec 31, 2025 | -4,125.32% |
| Sep 30, 2025 | -357.38% |
| Jun 30, 2025 | -168.51% |
| Mar 31, 2025 | 71.22% |
| Dec 31, 2024 | -47.75% |
| Sep 30, 2024 | -536.35% |
| Jun 30, 2024 | -532.19% |
| Mar 31, 2024 | -625.00% |
| Dec 31, 2023 | -957.71% |
| Sep 30, 2023 | -734.89% |
| Jun 30, 2023 | -1,226.72% |
| Mar 31, 2023 | -426.40% |
| Dec 31, 2022 | -768.88% |
| Sep 30, 2022 | -913.53% |
| Jun 30, 2022 | -781.31% |
| Mar 31, 2022 | -838.83% |